Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension

Metabolism: Clinical and Experimental

Volumn 55, Issue 9, 2006, Pages 1159-1164

  Benndorf, Ralf A ^a   Rudolph, Tanja ^a   Appel, Daniel ^a   Schwedhelm, Edzard ^a   Maas, Renke ^a   Schulze, Friedrich ^a   Silberhorn, Elisabeth ^a   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLUCOSE; INSULIN; LOSARTAN; NISOLDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TELMISARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASSAY; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MORBIDITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR INTRINSIC ACTIVITY; REPORTER GENE;

ADIPONECTIN; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BODY MASS INDEX; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; MIDDLE AGED; NISOLDIPINE; PPAR GAMMA;

EID: 33747131444     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.04.013     Document Type: Article

References (23)

1. Kjeldsen S.E., and Julius S. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 148 (2004) 747-754
2. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 64 (2004) 2537-2565
3. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350 (2004) 2362-2374
4. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
5. Schupp M., Janke J., Clasen R., Unger T., and Kinscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109 (2004) 2054-2057
6. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43 (2004) 993-1002
7. Yu Y.H., and Ginsberg H.N. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 96 (2005) 1042-1052
8. Schiffrin E.L. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 288 (2005) H1037-H1043
9. Clasen R., Schupp M., Foryst-Ludwig A., Sprang C., Clemenz M., Krikov M., et al. PPAR gamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46 (2005) 137-143
10. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetologia 23 (2000) 57-63
11. Vaccaro O., Masulli M., Cuomo V., Rivellese A.A., Uusitupa M., Vassby B., et al. Comparative evaluation of simple indices of insulin resistance. Metabolism 53 (2004) 1522-1526
12. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
13. Emoto M., Nishizawa Y., Maekawa K., Hiura Y., Kanda H., Kawagishi T., et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22 (1999) 818-822
14. Ferrannini E., Buzzigoli G., Bonadonna R., Giorico M.A., Oleggini M., Graziadei L., et al. Insulin resistance in essential hypertension. N Engl J Med 317 (1987) 350-357
15. Rao R.H. Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats. Am J Hypertens 7 (1994) 655-660
16. Sowers J.R. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286 (2004) H1597-H1602
17. Marrero M.B., Fulton D., Stepp D., and Stern D.M. Angiotensin II-induced insulin resistance and protein tyrosine phosphatases. Arterioscler Thromb Vasc Biol 24 (2004) 2009-2013
18. Guardiola-Diaz H.M., Rehnmark S., Usuda N., Albrektsen T., Feltkamp D., Gustafsson J.A., et al. Rat peroxisome proliferator-activated receptors and brown adipose tissue function during cold acclimatization. J Biol Chem 274 (1999) 23368-23377
19. Marrero M.B., Fulton D., Stepp D., and Stern D.M. Angiotensin II-induced insulin resistance and protein tyrosine phosphatases. Arterioscler Thromb Vasc Biol 24 (2004) 2009-2013
20. Vitale C., Mercuro G., Castiglioni C., Cornoldi A., Tulli A., Fini M., et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4 (2005) 6
21. Yavuz D., Koc M., Toprak A., Akpinar I., Velioglu A., Deyneli O., et al. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst 4 (2003) 197-203
22. Mallamaci F., Zoccali C., Cuzzola F., Tripepi G., Cutrupi S., Parlongo S., et al. Adiponectin in essential hypertension. J Nephrol 15 (2002) 507-511
23. Teo K., Yusuf S., Sleight P., Anderson C., Mookadam F., Ramos B., et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61